ReiThera and Exothera to develop low cost per dose manufacturing process to supply vaccines to LMICs


ReiThera Srl, an Italian biotechnology company dedicated to technology development, GMP manufacturing and clinical translation of genetic vaccines and drugs for advanced therapies, and Exothera, a full-service contract development and manufacturing organization (CDMO) in Belgium, entered into a collaboration agreement to develop a large-scale, low-cost-per-dose manufacturing process for the production of ReiThera’s new vaccines.

The collaboration will be funded by a €3 million grant from the Bill & Melinda Gates Foundation to develop and deliver novel, low-cost vaccines based on ReiThera’s GRAd technology platform, including against COVID-19 and HIV , mainly for the weak and middle-aged. Low Income Countries (PRITI) in Africa. Immunization remains one of the most effective and cost-effective public health interventions in low- and middle-income countries that are still struggling to ensure access to adequate supplies.

The large-scale manufacturing process will leverage Exothera’s unique expertise using the NevoLine™ Upstream platform (integrating the scale-X™ intensified fixed-bed nitro bioreactor), developed by sister company Exothera. ‘Exothera, Univercells Technologies. This innovative biomanufacturing technology has a very compact footprint while providing unparalleled cost-effective vaccine production.

Under the terms of the agreement, Exothera will develop the proprietary cell line in the NevoLine and infect them with the GRAd vector to create the bulk vaccine product, which ReiThera will then purify. The viral mass generated after the infection will be purified by a high-performance process developed by ReiThera.

ReiThera will start with its GRAd vector currently used in its COVID-19 vaccine candidate (GRAd-COV2) for the initial set-up of process development and will process it into final form for additional clinical trials in its state-of-the-art GMP facility. Manufacturing.


Comments are closed.